MYLAN PHARMACEUTICALS INC - NEW AWARD FOR THIORIDAZINE HCL TABLETS WITH MYLAN. PERIOD OF PERFORMANCE IS AUG 19, 2021 TO AUG 18, 2022 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR THIORIDAZINE HCL TABLETS WITH MYLAN. PERIOD OF PERFORMANCE IS AUG 19, 2021 TO AUG 18, 2022 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Jan 6, 2026, Department of Veterans Affairs to MYLAN PHARMACEUTICALS INC for new award for thioridazine hcl tablets with mylan. period of performance is aug 19, 2021 to aug 18, 2022 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.